Tamoxifen - Pioneering Medicine in Breast Cancer (Hardcover, 2013 ed.)

Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years. This monograph, written by V. Craig Jordan - known as the "father of tamoxifen" - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a "failed morning after contraceptive" to become the "gold standard" for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen's pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.

General

Imprint:	Springer Basel
Country of origin:	Switzerland
Series:	Milestones in Drug Therapy
Release date:	August 2013
First published:	2013
Authors:	Philipp Y. Maximov • Russell E. McDaniel • V.Craig Jordan
Dimensions:	235 x 155 x 18mm (L x W x T)
Format:	Hardcover
Pages:	199
Edition:	2013 ed.
ISBN-13:	978-3-03-480663-3
Categories:	Books > Medicine > Clinical & internal medicine > Endocrinology > General Books > Medicine > Other branches of medicine > Pharmacology > General Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology > General
LSN:	3-03-480663-9
Barcode:	9783034806633

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!